The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

AbbVie (NYSE:ABBV) is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of ...

While Humira’s 2023 loss of exclusivity hung over AbbVie’s head for years, the ascent of the Chicago drugmaker’s immunology successors Skyrizi and Rinvoq under prior CEO Richard Gonzalez has swiftl | ...

AbbVie (NYSE:ABBV) recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on March ...

ABBV’s Successful New Drugs — Skyrizi and Rinvoq AbbVie lost patent protection for Humira in the United States in January 2023 and in the EU in 2018. Humira's sales are declining due to the ...